In a patient with essential thrombocythemia whose platelet count decreased from 728 × 10⁹/L to 569 × 10⁹/L over 3 weeks while taking hydroxyurea 500 mg daily, should the hydroxyurea dose be increased?

Yes, increase the hydroxyurea dose now

Your patient's platelet count of 569 × 10⁹/L after 3 weeks on hydroxyurea 500 mg daily remains well above the therapeutic target of <400 × 10⁹/L, and the current dose is far below standard therapeutic levels—you should escalate the dose immediately. While the platelet trend shows response (728→569), this low starting dose (500 mg daily) is insufficient for adequate cytoreduction in essential thrombocythemia.

Rationale for Dose Escalation

The current clinical picture demonstrates:

• Subtherapeutic dosing: 500 mg daily is at the lower end of the therapeutic range
• Inadequate platelet control: Target is ≤400 × 10⁹/L for complete response 1
• Demonstrated drug tolerance: The patient has shown response without toxicity over 3 weeks
• Persistent thrombotic risk: Platelets >400 × 10⁹/L maintain elevated thrombosis risk

Dosing Algorithm

Increase hydroxyurea to 1000-1500 mg daily (typical therapeutic range is 15-20 mg/kg/day):

1. If patient weighs <70 kg: Increase to 1000 mg daily
2. If patient weighs ≥70 kg: Increase to 1500 mg daily
3. Monitor CBC weekly during dose escalation
4. Target platelet count: <400 × 10⁹/L (ideally 200-400 × 10⁹/L)

Monitoring Parameters During Escalation

Check complete blood count weekly and adjust dose based on:

• Platelet response: Should see further decline within 2-4 weeks
• Leukocyte count: Hold if <2.5 × 10⁹/L 1
• Hemoglobin: Hold if <10 g/dL 1
• Absolute neutrophil count: Hold if <1.0 × 10⁹/L 1

Critical Pitfalls to Avoid

Do not wait 3 months at inadequate doses: The NCCN criteria for hydroxyurea resistance/intolerance specify assessment after 3 months at doses of at least 2 g/day 1. Your patient is on 500 mg daily—far below this threshold. Premature labeling as "hydroxyurea-resistant" occurs when clinicians fail to adequately dose-escalate.

Do not accept platelets >400 × 10⁹/L: This leaves patients at unnecessary thrombotic risk. The landmark trial by Cortelazzo et al. demonstrated that maintaining platelets <600 × 10⁹/L with hydroxyurea reduced thrombosis from 24% to 3.6% 2, but current guidelines target <400 × 10⁹/L for optimal protection 3, 1.

When to Consider Alternative Agents

Only consider switching from hydroxyurea if the patient meets NCCN resistance/intolerance criteria 1:

• Platelet count >600 × 10⁹/L with WBC <2.5 × 10⁹/L at any dose
• Platelet count >400 × 10⁹/L with hemoglobin <10 g/dL at any dose
• Unacceptable toxicity (leg ulcers, mucocutaneous manifestations, fever)

Your patient meets none of these criteria—they simply need appropriate dose escalation.

Renal Function Consideration

Before escalating, verify renal function: If creatinine clearance is <60 mL/min, reduce the standard dose by 50% 4. In patients with normal renal function, proceed with full dose escalation as outlined above.

Adjunctive Therapy

Ensure the patient is on low-dose aspirin 81-100 mg daily if they are high-risk (age >60 or prior thrombosis) and have no contraindications 3. Aspirin combined with cytoreductive therapy reduces thrombotic events in this population.